ZEN is a nanotechnology company developing and commercializing next-gen healthcare solutions in the areas of prevention, detection, and treatment. ZEN is currently focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases. The company also has an exclusive agreement to be the global commercializing partner for a newly developed, aptamer-based rapid pathogen detection technology.
Reasons to Meet:
- ZEN is on the leading edge of innovative, potentially game-changing healthcare technologies that reduce the risk of pathogen transmission, the cost to businesses, our economy, and the healthcare system. We have IP or the rights to IP for:
- ZENGuard antimicrobial coating for the healthcare disposable PPE, and indoor air quality (HVAC) markets [Prevention]
- An aptamer-based, highly accurate, saliva-based, rapid detection technology that will serve as a longer-term platform for a highly scalable, fast, and accurate detection solution for several harmful pathogens, not just Covid [Detection]
- An antimicrobial therapeutic compound with incredible in-vitro efficacy against numerous pathogens, including common respiratory pathogens, fungi, and several antimicrobial-resistant bacteria. This broad-spectrum therapeutic will be a platform to potentially treat numerous pathogens via several different application methods in the future. While there are numerous indications we could target, our initial focus will be on dermatological applications to address widespread skin conditions.